INTRODUCTION: Immunotherapy has revolutionized the treatment of NSCLC, but little is known about the activity of programmed cell death 1 and programmed death ligand 1 blockade across age groups. METHODS: We retrospectively evaluated patients with NSCLC who initiated programmed cell death 1 and programmed death ligand 1 inhibitors from January 2013 through July 2017. Medical records and radiographic imaging were reviewed to determine progression-free survival (PFS) and overall survival (OS). We also compared immunotherapy-related toxicities, steroid use, and hospitalizations by age. RESULTS: Of the 245 patients, 26.1% were younger than 60 years, 31.4% were age 60 to 69 years, 31.0% were age 70 to 79 years, and 11.4% were age 80 years or older. The median PFS times by age group were as follows: younger than 60 years, 1.81 months; age 60 to 69 years, 2.53 months; age 70 to 79 years, 3.75 months; and age 80 years or older, 1.64 months (log-rank p value = 0.055). The median OS times by age group were as follows: younger than 60 years, 13.01 months; age 60 to 69 years, 14.56 months; age 70 to 79 years, 12.92 months; and age 80 years or older, 3.62 months (log-rank p value = 0.011). Rates of immunotherapy-related toxicities, steroid use, and hospitalizations did not differ by age. CONCLUSIONS: Although the OS and PFS benefits of immunotherapy differ by age, the rates of toxicity are similar regardless of age.
INTRODUCTION: Immunotherapy has revolutionized the treatment of NSCLC, but little is known about the activity of programmed cell death 1 and programmed death ligand 1 blockade across age groups. METHODS: We retrospectively evaluated patients with NSCLC who initiated programmed cell death 1 and programmed death ligand 1 inhibitors from January 2013 through July 2017. Medical records and radiographic imaging were reviewed to determine progression-free survival (PFS) and overall survival (OS). We also compared immunotherapy-related toxicities, steroid use, and hospitalizations by age. RESULTS: Of the 245 patients, 26.1% were younger than 60 years, 31.4% were age 60 to 69 years, 31.0% were age 70 to 79 years, and 11.4% were age 80 years or older. The median PFS times by age group were as follows: younger than 60 years, 1.81 months; age 60 to 69 years, 2.53 months; age 70 to 79 years, 3.75 months; and age 80 years or older, 1.64 months (log-rank p value = 0.055). The median OS times by age group were as follows: younger than 60 years, 13.01 months; age 60 to 69 years, 14.56 months; age 70 to 79 years, 12.92 months; and age 80 years or older, 3.62 months (log-rank p value = 0.011). Rates of immunotherapy-related toxicities, steroid use, and hospitalizations did not differ by age. CONCLUSIONS: Although the OS and PFS benefits of immunotherapy differ by age, the rates of toxicity are similar regardless of age.
Authors: Ajay Sheshadri; Alberto A Goizueta; Vickie R Shannon; David London; Guillermo Garcia-Manero; Hagop M Kantarjian; Farhad Ravandi-Kashani; Tapan M Kadia; Marina Y Konopleva; Courtney D DiNardo; Sherry Pierce; Abdulrazzak Zarifa; Aya A Albittar; Linda L Zhong; Fechukwu O Akhmedzhanov; Muhammad H Arain; Mansour Alfayez; Ahmad Alotaibi; Mehmet Altan; Aung Naing; Tito R Mendoza; Myrna C B Godoy; Girish Shroff; Sang T Kim; Saadia A Faiz; Dimitrios P Kontoyiannis; Fareed Khawaja; Kristofer Jennings; Naval G Daver Journal: Cancer Date: 2022-04-22 Impact factor: 6.921
Authors: Mitchell S von Itzstein; Amrit S Gonugunta; Helen G Mayo; John D Minna; David E Gerber Journal: Cancer J Date: 2020 Nov/Dec Impact factor: 2.074
Authors: Andrew C Johns; Lai Wei; Madison Grogan; Rebecca Hoyd; John F P Bridges; Sandipkumar H Patel; Mingjia Li; Marium Husain; Kari L Kendra; Gregory A Otterson; Jarred T Burkart; Ashley E Rosko; Barbara L Andersen; David P Carbone; Dwight H Owen; Daniel J Spakowicz; Carolyn J Presley Journal: J Geriatr Oncol Date: 2021-02-21 Impact factor: 3.929